<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2023-2-109-115</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1418</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Уратснижающая терапия и функция почек</article-title><trans-title-group xml:lang="en"><trans-title>Urate-lowering therapy and kidney function</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максим Сергеевич Елисеев</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Maxim Sergeevich Eliseev</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">elicmax@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2023</year></pub-date><volume>17</volume><issue>2</issue><fpage>109</fpage><lpage>115</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1418">https://mrj.ima-press.net/mrj/article/view/1418</self-uri><abstract><p>Хроническая гиперурикемия (ГУ) и подагра являются независимыми факторами риска снижения функции почек. В последнее десятилетие накапливаются данные о том, что уратснижающая терапия может быть эффективным методом замедления прогрессирования почечной недостаточности, опосредованной ГУ и подагрой. При этом основной целью терапии подагры является полное растворение кристаллов уратов, что приводит к излечению болезни, но невозможно без длительного приема уратснижающих препаратов. Вместе с тем лечение подагры при наличии хронического заболевания почек является намного более сложным и сопряжено с необходимостью учитывать потенциальное влияние лекарственных средств на достижение целевых значений уровня мочевой кислоты сыворотки и на функцию почек, а также прогнозировать риск развития нежелательных явлений. В статье представлены практические рекомендации, касающиеся применения уратснижающих препаратов у больных подагрой с хронической болезнью почек.</p></abstract><trans-abstract xml:lang="en"><p>Chronic hyperuricemia (CH) and gout are independent risk factors for decreased kidney function. In the last decade, evidence was accumulating that urate-lowering therapy may be an effective method of slowing down the progression of CH and gout-mediated renal failure. At the same time, the main goal of gout therapy is the complete resorption of urate crystals, which leads to resolution of the disease, but is impossible without longterm use of urate-lowering drugs. However, the treatment of gout in the presence of chronic kidney disease is much more complex and requires consideration of the potential impact of drugs on targeted serum uric acid level and on renal function, as well as predicting the risk of adverse events. The article presents practical recommendations regarding the use of urate-lowering drugs in gout patients with chronic kidney disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперурикемия</kwd><kwd>мочевая кислота</kwd><kwd>хроническая болезнь почек</kwd><kwd>фебуксостат</kwd><kwd>аллопуринол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hyperuricemia</kwd><kwd>uric acid</kwd><kwd>chronic kidney disease</kwd><kwd>febuxostat</kwd><kwd>allopurinol</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках фундаментальной научной темы «Разработка междисциплинарной персонализированной модели оказания помощи пациентам с аутовоспалительными дегенеративными заболеваниями (остеоартрит, остеопороз, саркопения, подагра, пирофосфатная артропатия) и мультиморбидностью (ожирение, сердечно-сосудистые заболевания)» №1021051403074-2. Статья спонсируется компанией АО «АКРИХИН»</funding-statement><funding-statement xml:lang="en">The article has been conducted within fundamental scientific topic “Development of an interdisciplinary personalized model of care for patients with autoinflammatory degenerative diseases (osteoarthritis, osteoporosis, sarcopenia, gout, pyrophosphate arthropathy) and multimorbidity (obesity, cardiovascular diseases)” №1021051403074-2. The article is sponsored by AKRIKHIN.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017 Nov;13(11):639-47. doi: 10.1038/nrrheum.2017.155.</mixed-citation><mixed-citation xml:lang="en">So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017 Nov;13(11):639-47. doi: 10.1038/nrrheum.2017.155.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рамеев ВВ, Елисеев МС, Моисеев СВ. Концепция аутовоспаления в генезе подагры и гиперурикемии. Клиническая фармакология и терапия. 2019;28(2):28-33.</mixed-citation><mixed-citation xml:lang="en">Rameev VV, Eliseev MS, Moiseev SV. The concept of auto-inflammation in the genesis of gout and hyperuricemia. Klinicheskaya farmakologiya i terapiya. 2019;28(2): 28-33. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disabilityadjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1859-922. doi: 10.1016/S0140-6736(18)32335-3.</mixed-citation><mixed-citation xml:lang="en">GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disabilityadjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1859-922. doi: 10.1016/S0140-6736(18)32335-3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Kidney Day: Chronic Kidney Disease. 2015; http://www.worldkidneyday.org/faqs/chronic-kidney-disease/</mixed-citation><mixed-citation xml:lang="en">World Kidney Day: Chronic Kidney Disease. 2015; http://www.worldkidneyday.org/faqs/chronic-kidney-disease/</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016 Jul 6;11(7):e0158765. doi: 10.1371/journal.pone.0158765. eCollection 2016.</mixed-citation><mixed-citation xml:lang="en">Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016 Jul 6;11(7):e0158765. doi: 10.1371/journal.pone.0158765. eCollection 2016.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888): 260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.</mixed-citation><mixed-citation xml:lang="en">Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888): 260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Хроническая болезнь почек: роль гиперурикемии и возможности уратснижающей терапии. Современная ревматология. 2018; 12(1):60-5. doi: 10/14412/1996-70122018-1-60-65</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy.Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018; 12(1): 60-5. (In Russ.). doi: 10/14412/1996-70122018-1-60-65</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012 Oct;42(2):166-78. doi: 10.1016/j.semarthrit.2012.03.013.</mixed-citation><mixed-citation xml:lang="en">Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012 Oct;42(2):166-78. doi: 10.1016/j.semarthrit.2012.03.013.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1 expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med. 2015 May;35(5):1347-54. doi: 10.3892/ijmm.2015.2148.</mixed-citation><mixed-citation xml:lang="en">Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1 expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med. 2015 May;35(5):1347-54. doi: 10.3892/ijmm.2015.2148.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960 Dec;39: 405-67.</mixed-citation><mixed-citation xml:lang="en">Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960 Dec;39: 405-67.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014 Jul 27;15: 122. doi: 10.1186/1471-2369-15-122.</mixed-citation><mixed-citation xml:lang="en">Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014 Jul 27;15: 122. doi: 10.1186/1471-2369-15-122.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li YL, Wang L, Li J, et al. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):555-61.</mixed-citation><mixed-citation xml:lang="en">Li YL, Wang L, Li J, et al. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. Zhonghua Nei Ke Za Zhi. 2011 Jul;50(7):555-61.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol. 2019 Mar 15;20(1):93. doi: 10.1186/s12882019-1274-5.</mixed-citation><mixed-citation xml:lang="en">Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol. 2019 Mar 15;20(1):93. doi: 10.1186/s12882019-1274-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jaffe DH, Klein AB, Benis A, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019 Mar 19;3:11. doi: 10.1186/s41927-019-0060-0. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Jaffe DH, Klein AB, Benis A, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019 Mar 19;3:11. doi: 10.1186/s41927-019-0060-0. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Stamp LK, Taylor WJ. What is remission in gout and how should we measure it? Rheumatology (Oxford). 2021 Mar 2;60(3): 1007-9. doi: 10.1093/rheumatology/keaa853.</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Stamp LK, Taylor WJ. What is remission in gout and how should we measure it? Rheumatology (Oxford). 2021 Mar 2;60(3): 1007-9. doi: 10.1093/rheumatology/keaa853.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-9.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Updated EULAR recommendations for the treatment of gout. Comments on some positions. Nauchno-prakticheskaya revmatologiya. 2017;55(6):600-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022 Dec 5;8(2):229-39. doi: 10.1016/j.ekir.2022.11.016.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022 Dec 5;8(2):229-39. doi: 10.1016/j.ekir.2022.11.016.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020 Oct;87(5):395-404. doi: 10.1016/j.jbspin.2020.05.002. Epub 2020 May 15.</mixed-citation><mixed-citation xml:lang="en">Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020 Oct;87(5):395-404. doi: 10.1016/j.jbspin.2020.05.002. Epub 2020 May 15.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Рекомендации Американской коллегии ревматологов (2020 г.) по ведению больных подагрой: что нового и что спорно. Научно-практическая ревматология. 2021;59(2):129-33.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Recommendations of the American College of Rheumatology (2020) on the management of patients with gout: what's new and what's controversial. Nauchno-prakticheskaya revmatologiya. 2021;59(2):129-33. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Чикина МН, Елисеев МС, Желябина ОВ. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020; 14(2):97-103. doi: 10.14412/1996-70122020-2-97-103.</mixed-citation><mixed-citation xml:lang="en">Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2): 97-103. (In Russ.). doi: 10.14412/1996-70122020-2-97-103.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sato Y, Feig DI, Stack AG, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019 Dec;15(12):767-75. doi: 10.1038/s41581-019-0174-z. Epub 2019 Jul 11.</mixed-citation><mixed-citation xml:lang="en">Sato Y, Feig DI, Stack AG, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019 Dec;15(12):767-75. doi: 10.1038/s41581-019-0174-z. Epub 2019 Jul 11.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020 Aug;33(4):715-24. doi: 10.1007/s40620-020-00702-7. Epub 2020 Jan 13.</mixed-citation><mixed-citation xml:lang="en">Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020 Aug;33(4):715-24. doi: 10.1007/s40620-020-00702-7. Epub 2020 Jan 13.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Trevino-Becerra A. Uric acid: the unknown uremic toxin. Contrib Nephrol. 2018; 192:25-33. doi: 10.1159/000484275. Epub 2018 Jan 23.</mixed-citation><mixed-citation xml:lang="en">Trevino-Becerra A. Uric acid: the unknown uremic toxin. Contrib Nephrol. 2018; 192:25-33. doi: 10.1159/000484275. Epub 2018 Jan 23.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a metaanalysis of 15 cohort studies. PLoS One. 2014 Jun 24;9(6):e100801. doi: 10.1371/journal.pone.0100801.</mixed-citation><mixed-citation xml:lang="en">Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a metaanalysis of 15 cohort studies. PLoS One. 2014 Jun 24;9(6):e100801. doi: 10.1371/journal.pone.0100801.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029.</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12): 2888-97. doi: 10.1097/01.asn.0000034910.58454.fd.</mixed-citation><mixed-citation xml:lang="en">Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12): 2888-97. doi: 10.1097/01.asn.0000034910.58454.fd.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009 Aug;297(2):F481-8. doi: 10.1152/ajprenal.00092.2009.</mixed-citation><mixed-citation xml:lang="en">Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009 Aug;297(2):F481-8. doi: 10.1152/ajprenal.00092.2009.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Oh TR, Choi HS, Kim CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019 Apr 30;9(1):6681. doi: 10.1038/s41598-019-43241-3.</mixed-citation><mixed-citation xml:lang="en">Oh TR, Choi HS, Kim CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019 Apr 30;9(1):6681. doi: 10.1038/s41598-019-43241-3.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Badve SV, Pascoe EM, Tiku A, et al; CKD-FIX Study Investigators. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020 Jun 25; 382(26):2504-13. doi: 10.1056/NEJMoa1915833.</mixed-citation><mixed-citation xml:lang="en">Badve SV, Pascoe EM, Tiku A, et al; CKD-FIX Study Investigators. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020 Jun 25; 382(26):2504-13. doi: 10.1056/NEJMoa1915833.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Doria A, Galecki AT, Spino et al; PERL Study Group. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 Jun 25;382(26): 2493-503. doi: 10.1056/NEJMoa1916624.</mixed-citation><mixed-citation xml:lang="en">Doria A, Galecki AT, Spino et al; PERL Study Group. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 Jun 25;382(26): 2493-503. doi: 10.1056/NEJMoa1916624.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Stanley IK, Phoon RKS, Toussaint ND, et al; CARI Guidelines Steering Committee. Caring for Australians and New Zealanders With Kidney Impairment Guidelines: Rapid Development of Urate Lowering Therapy Guidelines for People With CKD. Kidney Int Rep. 2022 Oct 5;7(12):2563-74. doi: 10.1016/j.ekir.2022.09.024.</mixed-citation><mixed-citation xml:lang="en">Stanley IK, Phoon RKS, Toussaint ND, et al; CARI Guidelines Steering Committee. Caring for Australians and New Zealanders With Kidney Impairment Guidelines: Rapid Development of Urate Lowering Therapy Guidelines for People With CKD. Kidney Int Rep. 2022 Oct 5;7(12):2563-74. doi: 10.1016/j.ekir.2022.09.024.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q, Wang Z, Zhou J, et al. Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1576-86. doi: 10.2215/CJN.05190420. Epub 2020 Oct 14.</mixed-citation><mixed-citation xml:lang="en">Chen Q, Wang Z, Zhou J, et al. Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1576-86. doi: 10.2215/CJN.05190420. Epub 2020 Oct 14.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Brown J, Mallory GK. Renal changes in gout. N Engl J Med. 1950 Aug 31;243(9): 325-9. doi: 10.1056/NEJM195008312430901.</mixed-citation><mixed-citation xml:lang="en">Brown J, Mallory GK. Renal changes in gout. N Engl J Med. 1950 Aug 31;243(9): 325-9. doi: 10.1056/NEJM195008312430901.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Y, Sun J. Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis. Appl Bionics Biomech. 2022 Jul 8;2022:9704862. doi: 10.1155/2022/9704862.</mixed-citation><mixed-citation xml:lang="en">Zheng Y, Sun J. Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis. Appl Bionics Biomech. 2022 Jul 8;2022:9704862. doi: 10.1155/2022/9704862.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lin TC, Hung LY, Chen YC, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Jul;98(29):e16311. doi: 10.1097/MD.0000000000016311.</mixed-citation><mixed-citation xml:lang="en">Lin TC, Hung LY, Chen YC, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Jul;98(29):e16311. doi: 10.1097/MD.0000000000016311.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tsukamoto S, Okami N, Yamada T, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):911-9. doi: 10.1007/s10067-02105956-5.</mixed-citation><mixed-citation xml:lang="en">Tsukamoto S, Okami N, Yamada T, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022 Mar;41(3):911-9. doi: 10.1007/s10067-02105956-5.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuji T, Ohishi K, Takeda A, et al. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2018 Dec;22(6):1300-8. doi: 10.1007/s10157-018-1580-4. Epub 2018 Apr 26.</mixed-citation><mixed-citation xml:lang="en">Tsuji T, Ohishi K, Takeda A, et al. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2018 Dec;22(6):1300-8. doi: 10.1007/s10157-018-1580-4. Epub 2018 Apr 26.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol.Clin Pharmacokinet. 1986 Sep-Oct;11(5):343-53. doi: 10.2165/00003088-198611050-00001.</mixed-citation><mixed-citation xml:lang="en">Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol.Clin Pharmacokinet. 1986 Sep-Oct;11(5):343-53. doi: 10.2165/00003088-198611050-00001.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.</mixed-citation><mixed-citation xml:lang="en">Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47-56. doi: 10.1016/0002-9343(84)90743-5.</mixed-citation><mixed-citation xml:lang="en">Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47-56. doi: 10.1016/0002-9343(84)90743-5.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Чикина МН, Желябина ОВ. Открытое 6-месячное исследование эффективности титрования дозы аллопуринола у пациентов с подагрой в рамках стратегии «лечение до цели». Русский медицинский журнал. 2022;(6):17-22.</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Чикина МН, Желябина ОВ. Открытое 6-месячное исследование эффективности титрования дозы аллопуринола у пациентов с подагрой в рамках стратегии «лечение до цели». Русский медицинский журнал. 2022;(6):17-22. [Eliseev MS, Chikina MN, Zhelyabina OV. An open 6-month study of the effectiveness of titration of the dose of allopurinol in patients with gout as part of the "treatment to goal" strategy. Russkii meditsinskii zhurnal. 2022; (6):17-22. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006 Aug;33(8):1646-50.</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006 Aug;33(8):1646-50.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.Ann Rheum Dis. 2017 Dec;76(12):2065-70. doi: 10.1136/annrheumdis-2017-211873.</mixed-citation><mixed-citation xml:lang="en">Stamp LK, Chapman PT, Barclay M, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.Ann Rheum Dis. 2017 Dec;76(12):2065-70. doi: 10.1136/annrheumdis-2017-211873.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Yokose C, Lu N, Xie H, et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ. 2019 Sep 30; 191(39):E1070-E1077. doi: 10.1503/cmaj.190339.</mixed-citation><mixed-citation xml:lang="en">Yokose C, Lu N, Xie H, et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ. 2019 Sep 30; 191(39):E1070-E1077. doi: 10.1503/cmaj.190339.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.</mixed-citation><mixed-citation xml:lang="en">Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019 Jun 7;40(22):1778-86. doi: 10.1093/eurheartj/ehz119.</mixed-citation><mixed-citation xml:lang="en">Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019 Jun 7;40(22):1778-86. doi: 10.1093/eurheartj/ehz119.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kielstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020 Oct 31;22(12):102. doi: 10.1007/s11906-02001116-3.</mixed-citation><mixed-citation xml:lang="en">Kielstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020 Oct 31;22(12):102. doi: 10.1007/s11906-02001116-3.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Влияние аллопуринола и фебуксостата на почечную функцию у пациентов с гиперурикемией и хронической болезнью почек. Эффективная фармакотерапия. 2021;17(17):16-20.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Effect of allopurinol and febuxostat on renal function in patients with hyperuricemia and chronic kidney disease. Effektivnaya farmakoterapiya. 2021;17(17):16-20. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu YO, Wu IW, Chang SH, et al. Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis. Clin Pharmacol Ther. 2020 May; 107(5):1159-69. doi: 10.1002/cpt.1697.</mixed-citation><mixed-citation xml:lang="en">Hsu YO, Wu IW, Chang SH, et al. Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis. Clin Pharmacol Ther. 2020 May; 107(5):1159-69. doi: 10.1002/cpt.1697.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Quilis N, Andrйs M, Gil S, et al. Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Arthritis Rheumatol. 2016 Oct;68(10): 2563-4. doi: 10.1002/art.39769.</mixed-citation><mixed-citation xml:lang="en">Quilis N, Andrйs M, Gil S, et al. Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Arthritis Rheumatol. 2016 Oct;68(10): 2563-4. doi: 10.1002/art.39769.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.Joint Bone Spine. 2017 Oct;84(5):595-8. doi: 10.1016/j.jbspin.2016.09.020.</mixed-citation><mixed-citation xml:lang="en">Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.Joint Bone Spine. 2017 Oct;84(5):595-8. doi: 10.1016/j.jbspin.2016.09.020.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Saag KG, Whelton A, Becker MA, et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654.</mixed-citation><mixed-citation xml:lang="en">Saag KG, Whelton A, Becker MA, et al. Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Чикина МН, Тхакоков ММ. Эффективность фебуксостата у пациентов с подагрой в зависимости от функции почек. Русский медицинский журнал. Медицинское обозрение. 2022;6(3):140-7.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Zhelyabina OV, Chikina MN, Tkhakokov MM. Efficacy of febuxostat in patients with gout depending on renal function. Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2022;6(3):140-7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011 Sep;38(9):1957-9. doi: 10.3899/jrheum110092.</mixed-citation><mixed-citation xml:lang="en">Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011 Sep;38(9):1957-9. doi: 10.3899/jrheum110092.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715.</mixed-citation><mixed-citation xml:lang="en">Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ. Рациональное использование рекомендаций по применению уратснижающей терапии: клинические примеры. Современная ревматология. 2022;16(3):85-90. doi: 10.14412/19967012-2022-3-85-90</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Zhelyabina OV. Rational use of recommendations for urate-lowering therapy: clinical examples. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022; 16(3):85-90. (In Russ.). doi: 10.14412/19967012-2022-3-85-90</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Cole G. Evaluating development and production costs: tablets versus capsules. Pharmaceutical technology Europe. 1998;(5):17-26.</mixed-citation><mixed-citation xml:lang="en">Cole G. Evaluating development and production costs: tablets versus capsules. Pharmaceutical technology Europe. 1998;(5):17-26.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
